Nurix Therapeutics, Inc. (NRIX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 11-30. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q3 '21: 10.3M Q4 '21: 7.4M Q1 '22: 9.6M Q2 '22: 11.4M Q3 '22: 10.8M Q4 '22: 6.8M Q1 '23: 12.7M Q2 '23: 30.7M Q3 '23: 18.5M Q4 '23: 15.2M Q1 '24: 16.6M Q2 '24: 12.1M Q3 '24: 12.6M Q4 '24: 13.3M Q1 '25: 18.5M Q2 '25: 44.1M Q3 '25: 7.9M Q4 '25: 13.6M Q1 '26: 6.3M Q2 '26: 9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -29M Q4 '21: -38M Q1 '22: -42.7M Q2 '22: -45.7M Q3 '22: -46.7M Q4 '22: -48.7M Q1 '23: -43M Q2 '23: -26.8M Q3 '23: -40M Q4 '23: -45.3M Q1 '24: -45.2M Q2 '24: -48.5M Q3 '24: -54.6M Q4 '24: -64.7M Q1 '25: -62.9M Q2 '25: -48.3M Q3 '25: -91.4M Q4 '25: -83.1M Q1 '26: -92.5M Q2 '26: -94.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -28.8M Q4 '21: -37.7M Q1 '22: -42.5M Q2 '22: -45.4M Q3 '22: -45.7M Q4 '22: -46.7M Q1 '23: -40.7M Q2 '23: -24.3M Q3 '23: -37M Q4 '23: -42M Q1 '24: -41.5M Q2 '24: -44.5M Q3 '24: -49M Q4 '24: -58.5M Q1 '25: -56.4M Q2 '25: -43.5M Q3 '25: -86.4M Q4 '25: -78.2M Q1 '26: -87.2M Q2 '26: -89.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -30M Q4 '21: -30.9M Q1 '22: -42.6M Q2 '22: -32.9M Q3 '22: -46.3M Q4 '22: -38M Q1 '23: -48.5M Q2 '23: -18.5M Q3 '23: -41.1M Q4 '23: 26.7M Q1 '24: -42M Q2 '24: -39.7M Q3 '24: -42.2M Q4 '24: -48.8M Q1 '25: -61.1M Q2 '25: -63.2M Q3 '25: -57.4M Q4 '25: -67.8M Q1 '26: -71.9M Q2 '26: -96.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -31.8M Q4 '21: -31.8M Q1 '22: -46.1M Q2 '22: -35.7M Q3 '22: -49.7M Q4 '22: -40.5M Q1 '23: -50.7M Q2 '23: -19.5M Q3 '23: -43.6M Q4 '23: 24.1M Q1 '24: -44.8M Q2 '24: -41.6M Q3 '24: -44.5M Q4 '24: -50.9M Q1 '25: -64.6M Q2 '25: -65.8M Q3 '25: -60.1M Q4 '25: -73M Q1 '26: -73M Q2 '26: -98.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '20: 4.9M Q3 '20: 16.9M Q2 '21: 43.8M Q3 '21: 44.4M Q1 '22: 44.7M Q2 '22: 44.9M Q3 '22: 50.9M Q1 '23: 54M Q2 '23: 54.3M Q3 '23: 54.4M Q1 '24: 54.9M Q2 '24: 62.4M Q3 '24: 72.8M Q1 '25: 83.6M Q2 '25: 83.9M Q3 '25: 84.2M Q1 '26: 110.1M Q2 '26: 111.1M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -2.39 Q4 '21: -2.73 Q1 '22: -3.05 Q2 '22: -3.46 Q3 '22: -3.71 Q4 '22: -3.72 Q1 '23: -3.52 Q2 '23: -2.96 Q3 '23: -2.74 Q4 '23: -2.65 Q1 '24: -2.66 Q2 '24: -2.92 Q3 '24: -2.91 Q4 '24: -2.89 Q1 '25: -2.80 Q2 '25: -2.61 Q3 '25: -2.97 Q4 '25: -3.05 Q1 '26: -3.17 Q2 '26: -3.46 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.